Hypercholesterolemia
Conditions
Keywords
endothelium, NO, renal, statins
Brief summary
The endothelium plays an important role in the regulation of vascular tone and regulation of blood flow. Nitric oxide (NO) is the most important known endothelium-derived vasodilating factor. Prospective studies have shown that hypercholesterolemia impairs endothelial function in different vascular beds. Lowering total cholesterol and particularly LDL-cholesterol with statins leads to an improvement in endothelium-dependent vasodilation in the forearm vasculature. There is strong evidence to suggest that the benefit is not merely related to the decrease in cholesterol-levels. A recent study in the forearm vasculature demonstrated that short-term lipid-lowering therapy improves endothelial function and NO availability already after 3 days of lipid lowering therapy. Whether endothelial function in the renal vasculature of hypercholesterolemic patients is similarly influenced has not yet been addressed adequately. In the present study we investigate whether lipid lowering therapy with rosuvastatin alters renal endothelial function, as assessed by systemic infusion of the NO synthase inhibitor L-NMMA, after 3 and 42 days of therapy.
Interventions
DRUGRosuvastatin
Sponsors
AstraZeneca
University of Erlangen-Nürnberg Medical School
Study design
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
PREVENTION
Masking
DOUBLE
Eligibility
Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
* Female and male patients aged between 18 and 75 years * fasting LDL C concentrations \>=160 and \< 250mg/dl * fasting TG concentrations =\< 350mg/dl
Exclusion criteria
* History of statin induced myopathy, or serious hypersensitivity reaction to other HMG-CoA reductase inhibitors (statins). * History of hypersensitivity reaction to inulin. * Lipid-lowering drugs (including lipid lowering dietary supplements of food additives) within the last 4 weeks. * Diabetes mellitus, defined as glycosylated hemoglobin (HbA1C) above the upper limit of normal (ULN). * Uncontrolled arterial hypertension (\>160/100mm Hg). * Subjects considered to be unstable (event within 12 weeks) by the investigator after the following events: a myocardial infarction, unstable angina, myocardial revascularisation (PTCA, CABG surgery or another revascularisation procedure) or a transient ischaemic attack (TIA) or stroke. * Significant arrythmias or conduction disturbances. * Congestive heart failure (NYHA classes III or IV). * Pregnant women, women who are breast feeding, and women of childbearing potential who are not using chemical or mechanical contraception or have positive serum pregnancy test (a serum beta-human chorionic gonadotropin analysis). * History of homozygous familial hypercholesterolaemia or known type III hyperlipoproteinemia (familial dysbetalipoproteinemia). * Use of concomitant medications. * Current active liver disease(SGPT \> 2xULN) or severe hepatic impairment. * Unexplained serum CK \> 3 times ULN (e.g. not due to recent trauma, intramuscular injections, heavy exercise etc.). * Serum creatinine \> 2,0 mg/dl and creatinine clearance \<80ml/min. * History of nephrolithiasis with calcium oxalate aggregation. * Uncontrolled hypothyroidism defined as a thyroid stimulating hormone (TSH) \> 1,5 times the UL or subjects whose thyroid replacement therapy was initiated within the last 3 month. * Severe disorders of the gastrointestinal tract or other diseases which interfere with the pharmacodynamics and pharmacokinetics of the study drug. * History of malignancy(unless a documented disease-free period exceeding 10 years is present) with the exception of basal cell or squamous cell carcinoma of the skin. Women with a history of cervical dysplasia would be permitted to enter the study provided they have 3 consecutive clear Papanicolaou (Pap) smears. * History of organ allografts. * Serious or unstable medical or psychological conditions that, in the opinion of the investigator, would compromise the subjects´s safety or successful participation in the trial. * Participation in a clinical study within 4 weeks preceding treatment start. * Past or present alcohol or drug abuse. * Suspected or confirmed poor compliance. * Previous enrolment in this study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Change in renal plasma flow from baseline in response to L-NMMA infusion after 6 weeks treatment with rosuvastatin. | — |
Secondary
| Measure | Time frame |
|---|---|
| Change in renal plasma flow from baseline in response to L-NMMA infusion after 3 days treatment with rosuvastatin. | — |
Countries
Germany
Outcome results
None listed